256 related articles for article (PubMed ID: 22069477)
21. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
22. Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer.
Bedard PL; Di Leo A; Piccart-Gebhart MJ
Nat Rev Clin Oncol; 2010 Jan; 7(1):22-36. PubMed ID: 19997076
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials.
Qian X; Li Z; Ruan G; Tu C; Ding W
Breast Cancer Res Treat; 2020 Jan; 179(2):275-285. PubMed ID: 31606823
[TBL] [Abstract][Full Text] [Related]
24. Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer.
Nowak AK; Wilcken NR; Stockler MR; Hamilton A; Ghersi D
Lancet Oncol; 2004 Jun; 5(6):372-80. PubMed ID: 15172358
[TBL] [Abstract][Full Text] [Related]
25. UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup.
D'Hondt V; Canon JL; Roca L; Levy C; Pierga JY; Le Du F; Campone M; Desmoulins I; Goncalves A; Debled M; Rios M; Ferrero JM; Serin D; Hardy-Bessard AC; Piot G; Brain E; Dohollou N; Orfeuvre H; Lemonnier J; Roché H; Delaloge S; Dalenc F
Eur J Cancer; 2019 Nov; 122():91-100. PubMed ID: 31634648
[TBL] [Abstract][Full Text] [Related]
26. Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer.
Sonnenblick A; Francis PA; Azim HA; de Azambuja E; Nordenskjöld B; Gutiérez J; Quinaux E; Mastropasqua MG; Ameye L; Anderson M; Lluch A; Gnant M; Goldhirsch A; Di Leo A; Barnadas A; Cortes-Funes H; Piccart M; Crown J
Eur J Cancer; 2015 Aug; 51(12):1481-9. PubMed ID: 26074397
[TBL] [Abstract][Full Text] [Related]
27. Platinum-based chemotherapy for early triple-negative breast cancer.
Mason SR; Willson ML; Egger SJ; Beith J; Dear RF; Goodwin A
Cochrane Database Syst Rev; 2023 Sep; 9(9):CD014805. PubMed ID: 37681577
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of 1-Year vs Shorter Durations of Adjuvant Trastuzumab Among Patients With Early Breast Cancer: An Individual Participant Data and Trial-Level Meta-analysis.
Gulia S; Kannan S; Badwe R; Gupta S
JAMA Netw Open; 2020 Aug; 3(8):e2011777. PubMed ID: 32833018
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials.
Ginés J; Sabater E; Martorell C; Grau M; Monroy M; Casado MA
Clin Transl Oncol; 2011 Jul; 13(7):485-98. PubMed ID: 21775276
[TBL] [Abstract][Full Text] [Related]
30. Taxane containing regimens for metastatic breast cancer.
Ghersi D; Wilcken N; Simes J; Donoghue E
Cochrane Database Syst Rev; 2005 Apr; (2):CD003366. PubMed ID: 15846659
[TBL] [Abstract][Full Text] [Related]
31. Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis.
Liu M; Liu S; Yang L; Wang S
BMC Cancer; 2021 Feb; 21(1):118. PubMed ID: 33541289
[TBL] [Abstract][Full Text] [Related]
32. Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial.
Fountzilas G; Dafni U; Papadimitriou C; Timotheadou E; Gogas H; Eleftheraki AG; Xanthakis I; Christodoulou C; Koutras A; Papandreou CN; Papakostas P; Miliaras S; Markopoulos C; Dimitrakakis C; Korantzopoulos P; Karanikiotis C; Bafaloukos D; Kosmidis P; Samantas E; Varthalitis I; Pavlidis N; Pectasides D; Dimopoulos MA
BMC Cancer; 2014 Jul; 14():515. PubMed ID: 25026897
[TBL] [Abstract][Full Text] [Related]
33. [Impact of taxanes in the adjuvant setting of node-negative breast cancers].
Lagha A; Chraiet N; Labidi S; Krimi S; Ayadi M; Gligorov J; Boussen H
Bull Cancer; 2013 May; 100(5):465-71. PubMed ID: 23613145
[TBL] [Abstract][Full Text] [Related]
34. Zoledronic acid as an adjuvant therapy in patients with breast cancer: a systematic review and meta-analysis.
Huang WW; Huang C; Liu J; Zheng HY; Lin L
PLoS One; 2012; 7(7):e40783. PubMed ID: 22844410
[TBL] [Abstract][Full Text] [Related]
35. Taxanes in the adjuvant treatment of early breast cancer, emerging consensus and unanswered questions.
Tang SC
Cancer Invest; 2009 Jun; 27(5):489-95. PubMed ID: 19479486
[TBL] [Abstract][Full Text] [Related]
36. Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials.
Estévez LG; Muñoz M; Alvarez I; Fernández Y; García-Mata J; Ruiz-Borrego M; Tusquets I; Seguí MA; Rodríguez-Lescure A; Adrover E; Lluch A
Cancer Treat Rev; 2007 Aug; 33(5):474-83. PubMed ID: 17561350
[TBL] [Abstract][Full Text] [Related]
37. [Taxanes in the adjuvant therapy of breastcancer with positive nodes: a meta-analysis].
Giménez Poderós T; Gaminde Inda I; Iruin Sanz A; Napal Lecumberri V
Farm Hosp; 2005 Mar; 29(2):75-85. PubMed ID: 16013929
[TBL] [Abstract][Full Text] [Related]
38. Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: a meta-analysis of phase III randomized control trials.
Shao N; Wang S; Yao C; Xu X; Zhang Y; Zhang Y; Lin Y
Breast; 2012 Jun; 21(3):389-93. PubMed ID: 22542064
[TBL] [Abstract][Full Text] [Related]
39. Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials.
Cuppone F; Bria E; Carlini P; Milella M; Felici A; Sperduti I; Nisticò C; Terzoli E; Cognetti F; Giannarelli D
Cancer; 2008 Jul; 113(2):238-46. PubMed ID: 18470908
[TBL] [Abstract][Full Text] [Related]
40. Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis.
Pajares B; Pollán M; Martín M; Mackey JR; Lluch A; Gavila J; Vogel C; Ruiz-Borrego M; Calvo L; Pienkowski T; Rodríguez-Lescure Á; Seguí MA; Tredan O; Antón A; Ramos M; Cámara Mdel C; Rodríguez-Martín C; Carrasco E; Alba E
Breast Cancer Res; 2013 Nov; 15(6):R105. PubMed ID: 24192331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
